The history of the erectile dysfunction drug presents a complex picture for shareholders. While the initial introduction generated significant gains, the lapse of its patent opened the avenue to generic versions, dramatically reducing sales. This poses a specific challenge for firms depending on comparable blockbuster offerings, suggesting that a c

The history of Viagra, and its developer copyright, presents a challenging case study for investors. Originally a blockbuster drug, yielding billions in revenue , its exclusivity period created a deluge of knock-off medications, significantly eroding its position . While specific firms may seek to capitalize on similar conditions , the current land